AR097963A1 - Antagonistas de receptor ep3 de prostaglandina - Google Patents

Antagonistas de receptor ep3 de prostaglandina

Info

Publication number
AR097963A1
AR097963A1 ARP140103751A ARP140103751A AR097963A1 AR 097963 A1 AR097963 A1 AR 097963A1 AR P140103751 A ARP140103751 A AR P140103751A AR P140103751 A ARP140103751 A AR P140103751A AR 097963 A1 AR097963 A1 AR 097963A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
alkyl
independently
antagonists
prostaglandina
Prior art date
Application number
ARP140103751A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR097963A1 publication Critical patent/AR097963A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP140103751A 2013-10-09 2014-10-08 Antagonistas de receptor ep3 de prostaglandina AR097963A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361888822P 2013-10-09 2013-10-09

Publications (1)

Publication Number Publication Date
AR097963A1 true AR097963A1 (es) 2016-04-20

Family

ID=51900918

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103751A AR097963A1 (es) 2013-10-09 2014-10-08 Antagonistas de receptor ep3 de prostaglandina

Country Status (9)

Country Link
US (1) US9278953B2 (enExample)
EP (1) EP3055300B1 (enExample)
JP (1) JP6348582B2 (enExample)
AR (1) AR097963A1 (enExample)
CA (1) CA2926568C (enExample)
ES (1) ES2665153T3 (enExample)
TW (1) TW201527297A (enExample)
UY (1) UY35776A (enExample)
WO (1) WO2015052610A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンep3受容体の拮抗薬
US10336701B2 (en) * 2017-08-10 2019-07-02 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists
US10399944B2 (en) 2017-08-10 2019-09-03 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists
US10590083B2 (en) 2017-08-10 2020-03-17 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists
WO2019219517A1 (en) * 2018-05-17 2019-11-21 Bayer Aktiengesellschaft Substituted dihydropyrazolo pyrazine carboxamide derivatives
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094208A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
WO2021094210A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
IL307374A (en) 2021-04-07 2023-11-01 Hadasit Med Res Service EP3 antagonists for the treatment of diabetes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PL201048B1 (pl) 1998-07-06 2009-03-31 Bristol Myers Squibb Co Bifenylosulfonamid jako dualny antagonista receptorów angiotensyny i endoteliny oraz jego zastosowanie
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
PL210793B1 (pl) 2001-02-28 2012-03-30 Merck & Co Inc Acylowane pochodne piperydyny
DE60301491T2 (de) 2002-02-27 2006-05-18 Pfizer Products Inc., Groton Acc-hemmer
DE602005015699D1 (de) 2004-05-12 2009-09-10 Pfizer Prod Inc Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
BRPI0510273A (pt) 2004-05-25 2007-10-30 Pfizer Prod Inc derivados de tetraazabenzo[e]azuleno e análogos destes
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
US20080200568A1 (en) 2005-08-30 2008-08-21 Stephanie Chissoe Genes Associated With Type ll Diabetes Mellitus
PT2463283E (pt) 2006-04-20 2014-08-27 Pfizer Prod Inc Compostos heterocíclicos de fenil amido condensados para a prevenção e tratamento de doenças mediadas pela glucoquinase
EA200900613A1 (ru) 2006-11-29 2009-10-30 Пфайзер Продактс Инк. Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US20110009443A1 (en) 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
JP5435592B2 (ja) 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
PL2334687T3 (pl) 2008-08-28 2012-05-31 Pfizer Pochodne dioksabicyklo[3.2.1]oktano-2,3,4-triolu
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
HRP20130661T1 (en) 2009-03-11 2013-08-31 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
US20110319379A1 (en) 2009-03-11 2011-12-29 Corbett Jeffrey W Substituted Indazole Amides And Their Use As Glucokinase Activators
CA2754523A1 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
JP2012526097A (ja) 2009-05-08 2012-10-25 ファイザー・インク Gpr119調節因子
JP2012526096A (ja) 2009-05-08 2012-10-25 ファイザー・インク Gpr119調節因子
GEP20135907B (en) 2009-06-05 2013-08-12 Pfizer L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof

Also Published As

Publication number Publication date
CA2926568A1 (en) 2015-04-16
CA2926568C (en) 2017-09-05
EP3055300B1 (en) 2018-03-07
JP6348582B2 (ja) 2018-06-27
JP2016532647A (ja) 2016-10-20
UY35776A (es) 2015-05-29
US20150099782A1 (en) 2015-04-09
ES2665153T3 (es) 2018-04-24
US9278953B2 (en) 2016-03-08
EP3055300A1 (en) 2016-08-17
TW201527297A (zh) 2015-07-16
WO2015052610A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
AR097963A1 (es) Antagonistas de receptor ep3 de prostaglandina
CY1124061T1 (el) Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες
AR102361A1 (es) Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
CR20140301A (es) Derivados de betulina
CL2023001369A1 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
MA35432B1 (fr) Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA201501122A8 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
MX2016006199A (es) Inhibidores de replicacion del virus de influenza.
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
DOP2018000196A (es) Metodos para tratar la depresion con antagonistas del receptor de orexina-2
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
ECSP14013239A (es) Composiciones farmacéuticas
AR094959A1 (es) Compuestos de imidazo piridina
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX346143B (es) Ligandos del receptor ep1.
EA201892726A1 (ru) Дейтерированный палбоциклиб
MX2015011932A (es) Moduladores de gpr120 de acido biciclo[2.2.2].
AR095097A1 (es) Compuestos de fenoxietoxi
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
CU24293B1 (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo

Legal Events

Date Code Title Description
FB Suspension of granting procedure